Is Eli Lilly’s Recent Obesity Drug Breakthrough Driving a Fair Stock Price in 2025?
If you’re holding Eli Lilly stock or eyeing it for your portfolio, you likely know it’s been on quite a ride lately. There’s a lot of chatter about whether now is the right time to buy, sell, or simply watch from the sidelines. After a massive 132.8% gain over three years and an incredible 554.4% return over the past five years, last year saw the stock dip by 9.4%, which certainly turned some heads. However, the longer-term story remains one of powerful growth, as seen in this month’s 7.6% climb despite a slight 1.7% drop over the last week.
Recent developments have been fueling both excitement and debate. The chatter largely centers on Eli Lilly’s breakthroughs in obesity and diabetes treatments. These innovations, especially…
